 |
|
Association Between 5- Reductase Inhibition and Risk of Hip Fracture
Steven J. Jacobsen, MD, PhD;
T. Craig Cheetham, PharmD, MS;
Reina Haque, PhD;
Jiaxiao M. Shi, PhD;
Ronald K. Loo, MD
JAMA. 2008;300(14):1660-1664.
Context For more than 15 years, 5- reductase inhibitors, which block the conversion of testosterone to dihydrotestosterone, have been used in the treatment of benign prostatic hyperplasia (BPH).Short-term studies show no effects of these agents on bone metabolism,but long-term data are not available.
Objective To assess the association between use of 5- reductase inhibitors (eg, finasteride) for BPH and occurrence of hip fracture.
Design, Setting, and Patients Population-based case-control study using data from Kaiser Permanente Southern California, a managed care organization with more than 3 million members. Case patients included 7076 men 45 years and older with incident hip fracture from 1997-2006. Control patients were 7076 men without incident hip fracture, optimally matched at a 1:1 ratio to case patients on age and medical center. Electronic information on pharmaceutical use was used to identify use of finasteride from 1991 forward.
Results Overall, 2547 (36%) and 2488 (35%) case and control patients, respectively, had a diagnosis of BPH (P = .30), and 109 (1.5%) and 141 (2.0%) of case and control patients, respectively, had been exposed to finasteride prior to the index date (matched odds ratio, 0.77; 95% confidence interval, 0.59-1.00; P = .04). There was no suggestion of a dose-response relationship between exposure to 5- reductase inhibitors when the exposure was stratified into tertiles of total exposure (P = .12). By contrast, there was a slightly higher prevalence of -blocker use in case vs control patients (32% vs 30%, respectively; P = .04).
Conclusions Exposure to 5- reductase inhibitors was not associated with increased risk of hip fracture. The reduction in risk observed with exposure to 5- reductase inhibitors and the modest increase in risk associated with exposure to -blockers require replication and warrant further investigation.
Author Affiliations: Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena (Drs Jacobsen, Haque, and Shi); Pharmacy Analytic Services, Kaiser Permanente Southern California, Downey (Dr Cheetham); and Department of Urology, Bellflower Medical Center, Kaiser Permanente Southern California, Bellfower (Dr Loo).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
All you need to read in the other general journals
BMJ 2008;337:a2061-a2061.
FULL TEXT
|
